Accelerating V940: A Strategic Blueprint for Translational to Late-Stage Clinical Development of Personalized Cancer Vaccines
Time: 11:00 am
day: Conference Day Two
Details:
• Integrating tumor profiling, neoantigen prediction, and manufacturing timelines to enable rapid patient-specific vaccine deployment
• Designing robust clinical trials to inform pivotal strategy: from patient selection to combination approaches
